Your position:
m.limatoxi.com
>>
EN
>>
EN
>>
Formulation
>>
The battle between Pfizer Gilead over COVID-19 drugs will continue
>> article
The battle between Pfizer Gilead over COVID-19 drugs will continue
Editor:xuezhe Clicks:
0
Date:2022-11-4 16:41:52
Keyword:
COVID-19 drugs
Healthoo Information:
The battle between Pfizer Gilead over COVID-19 drugs will continue
UserLogin
UserName：
Password：
The non-formal user may read the summary, the formal user can read the whole article。
please at once register the user of Heatlhoo.com
After registration, we will provide the sample reports and the more comprehensive consulting services for you.
UserName
Contact:
Title:
Mr.
Ms.
Password
Repeat password:
Mobile
Email
Verification code:
Company Name
E-mail:xuezhe@healthoo.com
Tel.:86-10-68032463
Our services:
China Im\Ex data service
Service fees of Chinese Vision
Our service items
Online information introduction
Monthly information
Relative Information
Market Report of Monoclonal Antibody Drugs in China (2022)
Innovative drugs - Medium long-term growth still has more room for imp...
Chinas innovative drugs entering the global market is the future trend...
In the first half of 2022, Chongqing exported about 880 million yuan o...
2022H1: Top 10 Best-Selling Drugs in the World
Pfizer to Increase Production Capacity of Coronavirus Oral Drugs, Inve...
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest ...
4 Innovative Drugs are Expected to be Approved by the FDA in June
Anke Bio Afana Collaborate on mRNA Vaccines for Mutant Strains Such as...
Anke Bio Afana Collaborate on mRNA Vaccines for Mutant Strains Such as...
Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
Tel:+86-10-68032463
map
